Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D8PE7D
|
|||
| Drug Name |
AVB-500
|
|||
| Drug Type |
Protein
|
|||
| Indication | IgA nephropathy [ICD-11: MF8Y] | Phase 2 | [1] | |
| Company |
Aravive
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | AXL receptor tyrosine kinase ligand (GAS6) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04042623) Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Aravive. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.